BlueRock Therapeutics LP

In News

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease - Bayer

Bayer - Oct 07, 2025

First Parkinson’s disease patient treated in BlueRock’s - GlobeNewswire

GlobeNewswire - Sep 22, 2025

First-in-Human Trial of OpCT-001: An iPSC-Derived Cell Therapy for Primary Photoreceptor Diseases - BioInformant

BioInformant - Jul 25, 2025

AI Boosts Parkinson’s Disease Cell Therapy Development - Citeline News & Insights

Citeline News & Insights - Nov 28, 2025

Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs - Fierce Biotech

Fierce Biotech - Jun 25, 2025

BlueRock Therapeutics announces publication in Nature of - GlobeNewswire

GlobeNewswire - Apr 16, 2025

First-Ever Dual Cell & Gene Therapy Approach: Bayer Launches Groundbreaking Parkinson's Disease Trials - Stock Titan

Stock Titan - Sep 22, 2025

Bayer-BlueRock Therapeutics bags USFDA Fast Track Designation for primary photoreceptor diseases... - Medical Dialogues

Medical Dialogues - Mar 03, 2025

BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial - PR Newswire

PR Newswire - Mar 14, 2023

BlueRock Therapeutics and Foundation Fighting Blindness collaborate to add new cohort to Uni-Rare study evaluating inherited retinal diseases - Ophthalmology Times

Ophthalmology Times - Mar 25, 2024

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel - CGTLive®

CGTLive® - Jul 22, 2024

Expansion into Europe for BlueRock Therapeutics - Labiotech.eu

Labiotech.eu - Jun 10, 2022

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment